Liminatus Pharma Finalizes Highly Dilutive $4.0M Public Offering to Fund Operations
Summary
Liminatus Pharma, a nano-cap immuno-oncology company, has finalized a $4.0 million public offering of common stock and warrants, securing critical capital for operations despite significant dilution.
Key Events
-
Finalized Public Offering
Liminatus Pharma closed a $4.0 million gross public offering of 8.27 million shares, 5.543 million pre-funded warrants, and 13.813 million common stock purchase warrants.
-
Dilutive Capital Raise
The offering, with net proceeds of $3.46 million, is highly dilutive, representing over 50% of the company's market capitalization.
-
Pricing Details
Securities were offered at $0.29 per unit, a slight premium to the current stock price of $0.2735, with common warrants exercisable at $0.29.
-
Placement Agent Compensation
Maxim Group LLC received an 8.0% cash fee and warrants to purchase 690,650 shares (5.0% of shares sold) at an exercise price of $0.319.
Analysis
This 8-K details the final terms and closing of Liminatus Pharma's public offering, which was previously registered via an S-1 filing on February 11, 2026, and finalized in a 424B4 on the same day as this 8-K. The company successfully raised $4.0 million in gross proceeds, with net proceeds of approximately $3.46 million, through the sale of common stock, pre-funded warrants, and common stock purchase warrants. The offering price of $0.29 per unit (shares and warrants) is notable as it is slightly above the current market price of $0.2735, indicating some investor confidence despite the company's distressed situation. However, the offering is highly dilutive, representing over 50% of the company's current market capitalization, and includes additional warrants for the placement agent. This capital infusion is crucial for Liminatus Pharma, which recently received a Nasdaq delisting notice and settled a major legal dispute, providing necessary funds for clinical trials, research and development, and general working capital to extend its operational runway.
At the time of this filing, LIMN was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.23 to $33.66. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.